Breast implant retrospective registry
This article was originally published in The Gray Sheet
Executive Summary
Current and former breast implant manufacturers met with device center staffers Feb. 9 to discuss development of the registry. Firms including Dow Corning, Mentor, Baxter Healthcare, Bioplasty, McGhan parent Inamed, Bristol- Myers Squibb and Surgitek are formulating plans to create a voluntary registry that would operate using industry funds. Discussions of the registry were initiated by FDA in April in response to the silicone gel-filled breast implant controversy ("The Gray Sheet" April 20, 1992, p. 1).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.